Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Supriya Lifescience is an active pharmaceutical ingredient (API) manufacturer with niche leadership in therapies such as antihistamines (notably chlorpheniramine maleate), anaesthetics (ketamine) and anti-allergics, operating from its Lote Parshuram (Maharashtra) site. It is strongly export-oriented, selling to regulated and semi-regulated markets across Europe, Latin America and Asia, with backward-integrated processes supporting margins.
It is among the world's leading suppliers in select antihistamine and anaesthetic API molecules.
Supriya Lifescience Ltd. is a constituent of NIFTY MICROCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Supriya Lifescience Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY25 (year ended 31 Mar 2025).
| Metric | FY25 | FY24 | FY23 |
|---|---|---|---|
| Free cash flow | ₹2 Cr | ₹-32 Cr | ₹-42 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹17 Cr |
| Debt to equity | 0.00 | 0.00 | 0.02 |
| Current ratio | 5.32 | 5.17 | 4.85 |
Open the full income statement, balance sheet and cash flow for SUPRIYA →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.